A Phase-2 Pilot Study of a Therapeutic Combination of Delta-9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette's Syndrome
Open-label, no control groupHumansWith delta-9-tetrahydrocannabinol (THC)
This study tested palmitoylethanolamide together with delta-9-tetrahydrocannabinol (THC). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 16 adults with treatment-refractory Tourette's syndrome
- Dose used in the study
- THX-110: THC up to 10 mg a day with a fixed 800 mg a day of PEA
- Duration
- 12 weeks, with a 24-week extension
- What was measured
- Yale Global Tic Severity Scale total tic score; comorbid symptoms; continuation into the extension
What the authors reported
Tic scores fell by about 7 points, over 20 percent, with a significant change within the first week. 12 of 16 continued into the extension. Side effects were common and were managed by lowering or slowing the THC dose.
Limits of this study
Uncontrolled and open label, 16 patients. The active partner is THC, a psychoactive drug, and the authors note that blinding such trials is hard. Nothing can be assigned to PEA. The product is a Yale-linked development compound.
Source
PubMed 34340527 · doi:10.1176/appi.neuropsych.19080178
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.